




Instance: composition-en-f2aa2b90d380444519f71c2efd9d6e1e
InstanceOf: CompositionUvEpi
Title: "Composition for sycrest Package Leaflet"
Description:  "Composition for sycrest Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf2aa2b90d380444519f71c2efd9d6e1e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sycrest"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Sycrest is and what it is used for </li>
<li>What you need to know before you take Sycrest </li>
<li>How to take Sycrest </li>
<li>Possible side effects </li>
<li>How to store Sycrest </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sycrest is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sycrest is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sycrest contains the active substance asenapine. This medicine belongs to a group of medicines called 
antipsychotics. Sycrest is used to treat moderate to severe manic episodes associated with bipolar I 
disorder in adults. Antipsychotic medicines affect the chemicals that allow communication between 
nerve cells (neurotransmitters). Illnesses that affect the brain, such as bipolar I disorder, may be due to 
certain chemicals in the brain, such as dopamine and serotonin, being out of balance and these 
imbalances may cause some of the symptoms you may be experiencing. Exactly how this medicine 
works is unknown, however, it is believed to adjust the balance of these chemicals. </p>
<p>Manic episodes associated with bipolar I disorder is a condition with symptoms such as feeling  high , 
having excessive amounts of energy, needing much less sleep than usual, talking very quickly with 
racing ideas and sometimes severe irritability. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sycrest"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sycrest"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Sycrest 
If you are allergic to asenapine or any of the other ingredients of this medicine (listed in section 6). </p>
<p>Warnings and precautions 
Talk to your doctor, pharmacist or nurse before taking Sycrest. </p>
<p>Sycrest has not been studied in elderly patients with dementia. However, elderly patients with 
dementia, who are treated with other similar types of medicine, may have an increased risk of stroke 
or death. Sycrest is not approved for the treatment of elderly patients with dementia and is not 
recommended for use in this particular group of patients.  </p>
<p>Sycrest may cause low blood pressure. In the early stages of treatment, some people may faint, 
especially when getting up from a lying or sitting position. This will usually pass on its own but if it 
does not, tell your doctor. Your dose may need to be adjusted. </p>
<p>Asenapine may cause sleepiness, sudden drops in blood pressure when you stand up, dizziness and 
changes in your ability to move and balance, which may lead to falls and, consequently, fractures or 
other injuries. Patients at risk for fall should be evaluated prior to prescribing asenapine. </p>
<p>Tell your doctor immediately if you experience </p>
<p>involuntary rhythmic movements of the tongue, mouth and face. Withdrawal of Sycrest may be 
needed. </p>
<p>fever, severe muscle stiffness, sweating or a lowered level of consciousness (a disorder called 
 neuroleptic malignant syndrome ). Immediate medical treatment may be needed. </p>
<p>Check with your doctor or pharmacist before taking Sycrest: </p>
<p>if you have ever been diagnosed with a condition whose symptoms include high body 
temperature and muscle stiffness (also known as neuroleptic malignant syndrome). </p>
<p>if you have ever experienced abnormal movements of the tongue or face (tardive dyskinesia). 
You should be aware that both of these conditions may be caused by this type of medicine. </p>
<p>if you have a heart disease or a treatment for heart disease that makes you prone to low blood 
pressure </p>
<p>if you are diabetic or prone to diabetes </p>
<p>if you have Parkinson s disease or dementia </p>
<p>if you have epilepsy (seizures) </p>
<p>if you experience any difficulty in swallowing (dysphagia) </p>
<p>if you have severe liver problems. If you do, you should not take Sycrest </p>
<p>if you have difficulty controlling core body temperature </p>
<p>if you have thoughts of suicide </p>
<p>if you have abnormally high levels of prolactin in the blood (hyperprolactinaemia) </p>
<p>Be sure to tell your doctor if you meet any of these conditions as he/she may want to adjust your dose 
or monitor you for a while. Also contact your doctor immediately if any of these conditions develops 
or worsens while using Sycrest. </p>
<p>Children and adolescents 
Sycrest is not recommended for use in patients below the age of 18 years. </p>
<p>Other medicines and Sycrest 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. Some medicines may reduce or increase the effect of Sycrest. </p>
<p>If you are taking other medicines, Sycrest should be taken last. </p>
<p>You should tell your doctor if you are taking antidepressant medicines (specifically fluvoxamine, 
paroxetine or fluoxetine), as it may be necessary to change your Sycrest or antidepressant medicine 
dose. </p>
<p>You should tell your doctor if you are taking medicines for Parkinson s disease (such as levodopa), as 
this medicine may make them less effective. </p>
<p>Since Sycrest works primarily in the brain, interference from other medicines (or alcohol) that work in 
the brain could occur due to an additive effect on brain function. </p>
<p>Since Sycrest can lower blood pressure, care should be taken when Sycrest is taken with other 
medicines that lower blood pressure. </p>
<p>Sycrest with food, drink and alcohol 
Do not eat or drink for 10 minutes after taking this medicine. 
You should avoid drinking alcohol when taking this medicine. 
Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Do not take Sycrest while you are pregnant, unless your doctor tells you so. If you are taking this 
medicine and you become pregnant or you plan to get pregnant, ask your doctor as soon as possible 
whether you may continue taking Sycrest. </p>
<p>The following symptoms may occur in newborn babies, of mothers that have used Sycrest in the last 
trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, 
agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms 
you may need to contact your doctor. </p>
<p>Do not breast-feed when taking Sycrest. </p>
<p>Driving and using machines 
Sycrest may cause sleepiness or sedation. Therefore, make sure your concentration and alertness are 
not affected before you drive or operate machinery. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sycrest"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sycrest"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is a sublingual tablet of 5 mg or 10 mg two times a day. One dose should be 
taken in the morning and one dose should be taken in the evening. </p>
<p>Instructions for use 
Sycrest is for sublingual use. 
Sycrest is not advised if you are unable to take the tablet as described below. If you are unable to take 
this medicine as is described below, the treatment may not be effective for you. 
- Do not remove a sublingual tablet from the blister until ready to take it.<br />
- Use dry hands when touching the tablet.<br />
- Do not push the tablet through the blister. Do not cut or tear the blister.<br />
- Peel back the coloured tab (Figure 1).<br />
- Gently remove the tablet (Figure 2). Do not crush the tablet. 
- To ensure optimal absorption, place the tablet under the tongue and wait until it dissolves 
completely (Figure 3). The tablet will dissolve in saliva within seconds.<br />
- Do not swallow or chew on the tablet.<br />
- Do not eat or drink for 10 minutes after taking the tablet. </p>
<p>Figure 1 
Figure 2 
Figure 3 </p>
<p>If you take more Sycrest than you should 
If you take too much Sycrest, contact a doctor straight away. Take the medicine pack with you. In case 
of overdose you may feel sleepy or tired, or have abnormal body movements, problems with standing 
and walking, feel dizzy due to low blood pressure and feel agitated and confused. </p>
<p>If you forget to take Sycrest 
Do not take a double dose to make up for a forgotten dose. If you miss one dose, take your next dose 
as usual. If you miss two or more doses, contact your doctor or pharmacist. </p>
<p>If you stop taking Sycrest 
If you stop taking Sycrest, you will lose the effects of this medicine. You should not stop taking this 
medicine, unless your doctor tells you as your symptoms may return. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Serious side effects have been reported with this medicine. Seek medical attention immediately if you 
have any of the following symptoms:</p>
<ul>
<li>allergic reactions (These usually involve a combination of effects such as difficulty in breathing 
or swallowing, swollen face, lips, tongue or throat, skin rash, itching and increased heart rate.) </li>
<li>sudden increase in body temperature, with sweating, fast heartbeat, severe muscle stiffness, 
confusion and fluctuating blood pressure which may lead to coma </li>
<li>convulsions, fits or seizures </li>
<li>fainting </li>
<li>falls which may occur as a result of one or more adverse events such as: sleepiness, sudden 
drops in blood pressure when you stand up, dizziness and changes in your ability to move and 
balance. </li>
</ul>
<p>Tell your doctor right away if you have:</p>
<ul>
<li>signs of increased blood sugar levels such as excessive thirst, hunger or urination, weakness or 
onset of worsening of diabetes </li>
<li>worm-like movements of the tongue, or other uncontrolled movements of the tongue, mouth, 
cheeks, or jaw which may progress to arms and legs </li>
</ul>
<p>Other side effects reported with this medicine include: </p>
<p>Very common side effects (may affect more than 1 in 10 people) 
- anxiety 
- sleepiness </p>
<p>Common side effects (may affect up to 1 in 10 people) 
- weight gain<br />
- increased appetite 
- slow or sustained muscle contractions<br />
- restlessness<br />
- involuntary muscle contractions<br />
- slow movements, tremor<br />
- sedation 
- dizziness 
- nausea 
- change in taste 
- numb feeling of the tongue or in the mouth 
- increased saliva (drooling) 
- muscle tightness 
- fatigue 
- increase in the level of liver proteins </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
- abnormal muscle movements: a collection of symptoms known as extrapyramidal symptoms 
(EPS) which may include one or more of the following: abnormal movements of muscles, 
tongue, or jaw, slow or sustained muscle contractions, muscle spasms, tremor (shaking), 
abnormal movements of the eyes, involuntary muscle contractions, slow movements, or 
restlessness<br />
- unpleasant sensations in the legs (also called restless legs syndrome) 
- speech problems<br />
- abnormal slow or fast heartbeat 
- middle heart block<br />
- abnormal electrocardiogram (prolongation of the QT interval) 
- low blood pressure upon standing 
- low blood pressure 
- tingling of the tongue or in the mouth<br />
- swollen or painful tongue<br />
- difficulty in swallowing 
- ulcers, soreness, redness, swelling, and blisters within the mouth 
- sexual dysfunction 
- lack of regular menstrual periods  </p>
<p>Rare side effects (may affect up to 1 in 1,000 people) 
- changes in the levels of white blood cells 
- difficulties in focusing with the eyes 
- blood clots in blood vessels to the lungs causing chest pain and difficulty in breathing 
- muscle disease presenting as unexplained aches and pains 
- male breast enlargement<br />
- leakage of milk or fluid from the breast </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sycrest"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sycrest"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and on the carton. The 
expiry date refers to the last day of that month. </p>
<p>Store this medicine in the original package in order to protect from light and moisture. </p>
<p>This medicinal product does not require any special temperature storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Sycrest contains </p>
<p>The active substance is asenapine.  </p>
<p>Each Sycrest 5 mg sublingual tablet contains 5 mg asenapine.  </p>
<p>Each Sycrest 10 mg sublingual tablet contains 10 mg asenapine. </p>
<p>The exact amount is shown on your Sycrest tablet pack. </p>
<p>The other ingredients are gelatin and mannitol (E421). </p>
<p>What Sycrest looks like and contents of the pack 
The 5 mg sublingual tablets are round white to off-white tablets marked with  5  on one side. 
The 10 mg sublingual tablets are round white to off-white tablets marked with  10  on one side. </p>
<p>The sublingual tablets are provided in peelable blisters containing 10 tablets each. Packs may contain 
20, 60 or 100 tablets.<br />
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
N.V. Organon 
Kloosterstraat 6 
NL-5349 AB Oss 
The Netherlands </p>
<p>Manufacturer 
Organon Heist bv 
Industriepark 2220 Heist-op-den-Berg, Belgium </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Organon Belgium 
T l/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Lietuva 
Organon Pharma B.V. Lithuania atstovyb<br />
Tel.: +370 52041dpoc.lithuania@organon.com </p>
<p>( . .)  . . -   <br />
 .: +359 2 806 3dpoc.bulgaria@organon.com<br />
Luxembourg/Luxemburg 
Organon Belgium 
T l/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>esk  republika 
Organon Czech Republic s.r.o. 
Tel: +420 233 010 dpoc.czech@organon.com </p>
<p>Magyarorsz g 
Organon Hungary Kft. 
Tel.: +36 1 766 1dpoc.hungary@organon.com </p>
<p>Danmark 
Organon Denmark ApS<br />
Tlf: +45 4484 6info.denmark@organon.com </p>
<p>Malta 
Organon Pharma B.V., Cyprus branch 
Tel: +356 2277 8dpoc.cyprus@organon.com </p>
<p>Deutschland 
Organon Healthcare GmbH 
Tel.: 0800 3384 726 (+49 (0) 89 2040022 10) 
dpoc.germany@organon.com </p>
<p>Nederland 
N.V. Organon 
Tel: 00800 66550123 (+32 2 2418100) 
dpoc.benelux@organon.com </p>
<p>Eesti 
Organon Pharma B.V. Estonian RO 
Tel: +372 66 61 dpoc.estonia@organon.com </p>
<p>Norge 
Organon Norway AS 
Tlf: +47 24 14 56 info.norway@organon.com </p>
<p>BIANE   . . 
 : +30 210 80091 Mailbox@vianex.gr </p>
<p>sterreich 
Organon Healthcare GmbH 
Tel: 0800 3384 726 (+49 (0) 89 2040022 10) 
dpoc.austria@organon.com </p>
<p>Espa a 
Organon Salud, S.L. 
Tel: +34 91 591 12 organon_info@organon.com 
Polska 
Organon Polska Sp. z o.o. 
Tel.: +48 22 105 50 organonpolska@organon.com </p>
<p>France 
Organon France 
T l: +33 (0) 1 57 77 32 Portugal 
Organon Portugal, Sociedade Unipessoal Lda. 
Tel: +351 218705geral_pt@organon.com </p>
<p>Hrvatska 
Organon Pharma d.o.o. 
Tel: +385 1 638 4dpoc.croatia@organon.com </p>
<p>Rom nia 
Organon Biosciences S.R.L. 
Tel: +40 21 527 29 dpoc.romania@organon.com </p>
<p>Ireland 
Organon Pharma (Ireland) Limited 
Tel: +353 15828medinfo.ROI@organon.com </p>
<p>Slovenija 
Organon Pharma B.V., Oss, podru nica 
Ljubljana 
Tel: +386 1 300 10 dpoc.slovenia@organon.com </p>
<p>sland 
Vistor hf. 
S mi: +354 535 7Slovensk  republika 
Organon Slovakia s. r. o. 
Tel: +421 2 44 88 98 dpoc.slovakia@organon.com </p>
<p>Italia 
Organon Italia S.r.l. 
Tel: +39 06 90259dpoc.italy@organon.com  </p>
<p>Suomi/Finland 
Organon Finland Oy 
Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com </p>
<p>Organon Pharma B.V., Cyprus branch 
 : +357 22866dpoc.cyprus@organon.com </p>
<p>Sverige 
Organon Sweden AB 
Tel: +46 8 502 597 dpoc.sweden@organon.com </p>
<p>Latvija 
 rvalsts komersanta  Organon Pharma B.V.<br />
p rst vniec ba 
Tel: +371 66968dpoc.latvia@organon.com </p>
<p>United Kingdom (Northern Ireland) 
Organon Pharma (UK) Limited<br />
Tel: +44 (0) 208 159 3medicalinformationuk@organon.com </p>
<p>This leaflet was last revised in {month/YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-f2aa2b90d380444519f71c2efd9d6e1e
InstanceOf: CompositionUvEpi
Title: "Composition for sycrest Package Leaflet"
Description:  "Composition for sycrest Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf2aa2b90d380444519f71c2efd9d6e1e)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sycrest"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Sycrest 
3. Sådan skal du tage Sycrest 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sycrest is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sycrest is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sycrest indeholder det aktive stof asenapin. Lægemidlet tilhører en medicingruppe, som kaldes 
antipsykotika. Sycrest anvendes til behandling af moderate til svære maniske episoder ved bipolar 
affektiv sindslidelse (Bipolar I lidelse) hos voksne. Antipsykotisk medicin påvirker nogle af de stoffer 
i hjernen, der tillader kommunikation mellem nerveceller (kaldet neurotransmittere). Sygdomme, der 
påvirker hjernen såsom bipolar I lidelse, kan skyldes ubalance af visse stoffer såsom dopamin og 
serotonin, og denne ubalance kan give nogle af de symptomer, som du måske oplever.  Det vides ikke 
præcist, hvordan lægemidlet virker. Det antages dog, at medicinen justerer balancen mellem disse 
stoffer. </p>
<p>Maniske episoder er en tilstand med symptomer såsom en følelse af at være "høj", have overdreven 
energi, mindre søvnbehov end normalt, tale meget hurtigt, have mange ideer og sommetider være 
meget irritabel. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sycrest"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sycrest"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Sycrest 
- hvis du er allergisk over for asenapin eller et af de øvrige indholdsstoffer i Sycrest (angivet i 
punkt 6).  </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager Sycrest. </p>
<p>Sycrest er ikke undersøgt hos ældre patienter med demens. Ældre patienter med demens, som er i 
behandling med lignende typer af medicin, kan dog have en øget risiko for slagtilfælde eller dødsfald. 
Sycrest er ikke godkendt til behandling af ældre patienter med demens og anbefales ikke til denne 
gruppe af patienter. </p>
<p>Sycrest kan give lavt blodtryk. Nogle patienter kan i det tidlige stadie af behandlingen besvime, 
specielt når de rejser sig fra en liggende eller siddende stilling. Dette vil sædvanligvis gå over af sig 
selv, men kontakt lægen hvis det ikke gør. Din dosis skal muligvis justeres. </p>
<p>Asenapin kan medføre søvnighed, pludseligt fald i blodtrykket, når du rejser dig op, svimmelhed samt 
ændret bevægelses- og balanceevne, som kan medføre fald og dermed også brud eller andre skader. 
Patienter med risiko for fald skal vurderes før ordination af asenapin. </p>
<p>Fortæl det omgående til din læge, hvis du oplever 
- ufrivillige rytmiske bevægelser af tunge, mund og ansigt. Det kan være nødvendigt at stoppe 
med at tage Sycrest. 
- feber, svær muskelstivhed, svedtendens eller nedsat bevidsthedsniveau (en lidelse kaldet malignt 
neuroleptikasyndrom). Omgående behandling kan være nødvendig. </p>
<p>Spørg din læge eller på apoteket, før du tager Sycrest:</p>
<ul>
<li>hvis du er blevet diagnosticeret med en tilstand med symptomer i form af høj kropstemperatur 
og muskelstivhed (også kendt som Neuroleptisk Malignt Syndrom) </li>
<li>hvis du har oplevet unormale bevægelser af tungen eller ansigtet (tardiv dyskinesi). Du skal 
være opmærksom på at begge tilstande kan skyldes denne type medicin. </li>
<li>hvis du har en hjertesygdom eller tager hjertemedicin, som kan give tilbøjelighed til lavt 
blodtryk </li>
<li>hvis du har sukkersyge eller har risiko for at få sukkersyge </li>
<li>hvis du har Parkinsons sygdom eller demens </li>
<li>hvis du har epilepsi (kramper) </li>
<li>hvis du oplever synkebesvær (dysfagi) </li>
<li>hvis du har alvorlige leverproblemer, må du ikke tage Sycrest. </li>
<li>hvis din krop har svært ved at regulere kropstemperaturen </li>
<li>hvis du har selvmordstanker. </li>
<li>hvis du har et unormalt højt indhold af hormonet prolaktin i blodet (hyperprolaktinæmi). </li>
</ul>
<p>Fortæl det til lægen, hvis du har nogle af disse tilstande, da han/hun vil justere din dosis eller følge dig 
et stykke tid. Kontakt også straks din læge, hvis du udvikler disse tilstande, eller de forværres, mens 
du tager Sycrest.  </p>
<p>Børn og unge 
Sycrest frarådes til patienter under 18 år. </p>
<p>Brug af anden medicin sammen med Sycrest 
Fortæl altid lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden 
medicin eller planlægger at tage anden medicin. Nogle lægemidler kan reducere eller øge virkningen 
af Sycrest. </p>
<p>Hvis du tager anden medicin, skal Sycrest tages til sidst. </p>
<p>Fortæl det til lægen, hvis du tager medicin mod depression (specielt fluvoxamin, paroxetin eller 
fluoxetin), da det kan være nødvendigt at ændre dosis af Sycrest eller den antidepressive medicin. </p>
<p>Fortæl det til lægen, hvis du tager medicin for Parkinsons sygdom (såsom levodopa), da Sycrest kan 
reducere virkningen af denne type medicin. </p>
<p>Da Sycrest primært virker i hjernen, kan der opstå forstyrrelser fra anden medicin (eller alkohol), som 
også påvirker hjernens funktion.  </p>
<p>Da Sycrest kan sænke blodtrykket, skal du være forsigtig, når Sycrest tages sammen med anden 
medicin, der nedsætter blodtrykket.  </p>
<p>Brug af Sycrest sammen med mad, drikke og alkohol 
Du må ikke spise eller drikke i 10 minutter, efter du har taget dette lægemiddel. 
Du skal undgå at drikke alkohol, mens du tager dette lægemiddel. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Du må ikke tage Sycrest, mens du er gravid, medmindre din læge har sagt, du skal gøre det. Tal straks 
med lægen om du skal fortsætte med dette lægemiddel, hvis du bliver gravid eller har planer om at 
blive gravid. </p>
<p>Følgende symptomer kan forekomme hos nyfødte af mødre, som har taget Sycrest i sidste trimester 
(de sidste tre måneder af graviditeten): rystelser, muskelstivhed og/eller svaghed, søvnighed, rastløs 
uro, vejrtrækningsbesvær og besvær med at indtage føde. Hvis dit barn får nogle af disse symptomer, 
skal du kontakte din læge. </p>
<p>Du må ikke amme, mens du tager Sycrest. </p>
<p>Trafik- og arbejdssikkerhed 
Sycrest kan medføre søvnighed eller virke sløvende. Vær opmærksom på, hvordan medicinen påvirker 
dig, og sørg derfor for, at din koncentrationsevne eller opmærksomhed ikke er påvirket, inden du kører 
eller arbejder med maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sycrest"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sycrest"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet.  </p>
<p>Den sædvanlige dosis er 1 sublingual resoriblet (til placering under tungen) på 5 mg eller 10 mg 2 
gange dagligt. Du skal tage en dosis om morgenen og en dosis om aftenen. </p>
<p>Brugervejledning 
Sycrest er til anvendelse under tungen. 
Sycrest frarådes, hvis du ikke er i stand til at tage resoribletten som beskrevet nedenfor. Hvis du ikke 
er i stand til at tage dette lægemiddel, som beskrevet nedenfor, er det ikke sikkert, at behandlingen er 
effektiv for dig. 
- Tag ikke resoribletten ud af blisterpakningen før du er klar til at tage den. 
- Dine hænder skal være tørre, når du rører ved resoribletten. 
- Pres ikke resoribletten ud af blisterpakningen. Du må ikke skære i eller rive i blisterpakningen. 
- Træk i den farvede flap (figur 1). 
- Tag forsigtigt resoribletten ud (figur 2). Knus ikke resoribletten. 
- Placer resoribletten under tungen og vent til den er helt opløst (figur 3). Resoribletten opløses i 
spyt inden for få sekunder. 
- Du må ikke synke eller tygge resoribletten. 
- Du må ikke spise eller drikke i 10 minutter efter, at du har taget resoribletten. </p>
<p>Figur 1 </p>
<pre><code>  Figur 2
</code></pre>
<p>Figur 3 </p>
<p>Hvis du har taget for meget Sycrest 
Kontakt straks lægen, hvis du har taget for meget Sycrest. Tag medicinpakken med dig. I tilfælde af 
overdosering kan du føle dig søvnig eller træt, eller have unormale kropsbevægelser, problemer med 
at stå og gå, føle dig svimmel pga. lavt blodtryk og føle dig irritabel og forvirret. </p>
<p>Hvis du har glemt at tage Sycrest 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. Tag den næste dosis som du 
plejer, hvis du har glemt en dosis. Kontakt din læge eller apoteket, hvis du har glemt to eller flere 
doser. </p>
<p>Hvis du holder op med at tage Sycrest 
Du mister virkningen af denne medicin, hvis du holder op med at tage Sycrest. Du må ikke holde op 
med at tage dette lægemiddel, medmindre din læge beder dig om det, da symptomerne kan vende 
tilbage. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Der er indberettet alvorlige bivirkninger i forbindelse med dette lægemiddel. Kontakt straks en læge, 
hvis du oplever et eller flere af følgende symptomer:</p>
<ul>
<li>allergiske reaktioner (omfatter som regel flere symptomer såsom problemer med at trække 
vejret eller synke, hævet ansigt, læber, tunge eller svælg, hududslæt, kløe og øget hjertefrekvens 
(puls)) </li>
<li>pludseligt øget kropstemperatur med øget svedproduktion, hurtige hjerteslag, svær 
muskelstivhed, forvirring og svingende blodtryk, som kan føre til koma </li>
<li>krampetrækninger eller krampeanfald </li>
<li>besvimelse </li>
<li>fald, som kan ske som et resultat af en eller flere bivirkninger såsom: søvnighed, pludseligt fald 
i blodtrykket, når du rejser dig op, svimmelhed og ændret bevægelses- og balanceevne. </li>
</ul>
<p>Fortæl det straks til lægen, hvis du har:</p>
<ul>
<li>tegn på forhøjet blodsukker såsom overdreven tørst, sult eller vandladning, svaghed eller 
begyndende forværring af diabetes (sukkersyge) </li>
<li>vridende tungebevægelser eller andre ufrivillige bevægelser af tunge-, mund-, eller kæber, som 
kan sprede sig til arme og ben. </li>
</ul>
<p>Andre bivirkninger, som er indberettet for dette lægemiddel, inkluderer: </p>
<p>Meget almindelige bivirkninger (kan påvirke flere end 1 ud af 10) 
- angst 
- søvnighed. </p>
<p>Almindelige bivirkninger (kan påvirke op til 1 ud af 10) 
- vægtstigning 
- øget appetit 
- langsomme og vedvarende muskelsammentrækninger 
- rastløshed 
- ufrivillige muskelsammentrækninger 
- langsomme bevægelser, rysten 
- sløvhed 
- svimmelhed 
- kvalme 
- forandringer i smagssansen 
- følelsesløshed af tungen eller i munden 
- øget spytproduktion (savlen) 
- muskelstramhed 
- træthed 
- forhøjet niveau af leverenzymer. </p>
<p>Ikke almindelige bivirkninger (kan påvirke op til 1 ud af 100) 
- unormale muskelbevægelser: en samling af symptomer kendt som ekstrapyramidale symptomer 
(EPS), som inkluderer en eller flere af følgende: unormale bevægelser af muskler, tunge eller 
kæbe, langsomme eller vedvarende muskelsammentrækninger, muskelspasmer, rysten 
(skælven), unormale bevægelser af øjet, ufrivillige muskelsammentrækninger, langsomme 
bevægelser eller rastløshed 
- ubehagelig fornemmelse eller uro i benene (også kaldet restless legs) 
- taleproblemer 
- unormalt langsom eller hurtig hjerterytme (puls) 
- hjerteblok 
- unormalt elektrokardiogram (forlængelse af QT-intervallet) 
- lavt blodtryk når man rejser sig 
- lavt blodtryk 
- prikkende fornemmelse i tungen eller i munden 
- hævelse eller smerte i tungen 
- synkebesvær 
- sår, ømhed, rødme, hævelse og blærer i munden 
- seksuel dysfunktion 
- manglende eller uregelmæssige menstruationsperioder. </p>
<p>Sjældne bivirkninger (kan påvirke op til 1 ud af 1.000) 
- ændringer i antallet af hvide blodlegemer 
- besvær med at fokusere med øjnene 
- blodpropper i blodkar til lungerne som forårsager brystsmerter og vejrtrækningsbesvær 
- muskellidelse som viser sig ved uforklarlige ømheder og smerter<br />
- forstørrelser af brysterne hos mænd 
- mælk eller væske siver ud fra brysterne. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sycrest"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sycrest"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på blisteren og kartonen efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Opbevar lægemidlet i den originale yderpakning for at beskytte mod lys og fugt. </p>
<p>Der er ingen særlige krav vedrørende opbevaringstemperaturer for dette lægemiddel. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sycrest indeholder:</p>
<ul>
<li>Aktivt stof: Asenapin.  </li>
<li>Hver Sycrest 5 mg sublingual resoriblet indeholder 5 mg asenapin. </li>
<li>Hver Sycrest 10 mg sublingual resoriblet indeholder 10 mg asenapin. </li>
<li>Den præcise mængde er angivet på Sycrest pakningen.  </li>
<li>Øvrige indholdsstoffer: Gelatine og mannitol (E421). </li>
</ul>
<p>Udseende og pakningsstørrelser 
Sycrest 5 mg sublinguale resoribletter er runde, hvide til råhvide resoribletter mærket med "5" på den 
ene side. 
Sycrest 10 mg sublinguale resoribletter er runde, hvide til råhvide resoribletter mærket med "10" på 
den ene side. </p>
<p>De sublinguale resoribletter leveres i oplukkelige (ved træk i den farvede flap) blisterpakninger, som 
indeholder 10 resoribletter hver. Pakningen kan indeholde 20, 60 eller 100 resoribletter. 
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
N.V. Organon 
Kloosterstraat 6 
NL-5349 AB Oss 
Holland </p>
<p>Fremstiller 
Organon Heist bv 
Industriepark 2220 Heist-op-den-Berg, Belgien </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Organon Belgium 
Tél/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Lietuva 
Organon Pharma B.V. Lithuania atstovybė 
Tel.: +370 52041dpoc.lithuania@organon.com </p>
<p>България 
Органон (И.А.) Б.В. - клон България 
Тел.: +359 2 806 3dpoc.bulgaria@organon.com  </p>
<p>Luxembourg/Luxemburg 
Organon Belgium 
Tél/Tel: 0080066550123 (+32 2 2418100)<br />
dpoc.benelux@organon.com </p>
<p>Česká republika 
Organon Czech Republic s.r.o. 
Tel: +420 233 010 dpoc.czech@organon.com  </p>
<p>Magyarország 
Organon Hungary Kft. 
Tel.: +36 1 766 1dpoc.hungary@organon.com 
Danmark 
Organon Denmark ApS 
Tlf: +45 4484 6info.denmark@organon.com </p>
<p>Malta 
Organon Pharma B.V., Cyprus branch 
Tel: +356 2277 8dpoc.cyprus@organon.com </p>
<p>Deutschland 
Organon Healthcare GmbH 
Tel.: 0800 3384 726 (+49 (0) 89 2040022 10) 
dpoc.germany@organon.com </p>
<p>Nederland 
N.V. Organon 
Tel: 00800 66550123 (+32 2 2418100) 
dpoc.benelux@organon.com </p>
<p>Eesti 
Organon Pharma B.V. Estonian RO 
Tel: +372 66 61 dpoc.estonia@organon.com </p>
<p>Norge 
Organon Norway AS 
Tlf: +47 24 14 56 info.norway@organon.com </p>
<p>Ελλάδα 
BIANEΞ Α.Ε. 
Τηλ: +30 210 80091 Mailbox@vianex.gr </p>
<p>Österreich 
Organon Healthcare GmbH 
Tel: 0800 3384 726 (+49 (0) 89 2040022 10) 
dpoc.austria@organon.com 
España 
Organon Salud, S.L. 
Tel: +34 91 591 12 organon_info@organon.com 
Polska 
Organon Polska Sp. z o.o. 
Tel.: +48 22 105 50 organonpolska@organon.com </p>
<p>France 
Organon France 
Tél: +33 (0) 1 57 77 32  </p>
<p>Portugal 
Organon Portugal, Sociedade Unipessoal Lda. 
Tel: +351 218705geral_pt@organon.com </p>
<p>Hrvatska 
Organon Pharma d.o.o. 
Tel: +385 1 638 4dpoc.croatia@organon.com </p>
<p>România 
Organon Biosciences S.R.L. 
Tel: +40 21 527 29 dpoc.romania@organon.com </p>
<p>Ireland 
Organon Pharma (Ireland) Limited 
Tel: +353 15828medinfo.ROI@organon.com </p>
<p>Slovenija 
Organon Pharma B.V., Oss, podružnica Ljubljana 
Tel: +386 1 300 10 dpoc.slovenia@organon.com </p>
<p>Ísland 
Vistor hf. 
Sími: +354 535 7 
Slovenská republika 
Organon Slovakia s. r. o. 
Tel: +421 2 44 88 98 dpoc.slovakia@organon.com </p>
<p>Italia 
Organon Italia S.r.l. 
Tel: +39 06 90259dpoc.italy@organon.com  </p>
<p>Suomi/Finland 
Organon Finland Oy 
Puh/Tel: +358 (0) 29 170 3dpoc.finland@organon.com </p>
<p>Κύπρος 
Organon Pharma B.V., Cyprus branch 
Τηλ: +357 22866dpoc.cyprus@organon.com </p>
<p>Sverige 
Organon Sweden AB 
Tel: +46 8 502 597 dpoc.sweden@organon.com </p>
<p>Latvija 
Ārvalsts komersanta “Organon Pharma B.V." 
pārstāvniecība 
Tel: +371 66968dpoc.latvia@organon.com </p>
<p>United Kingdom (Northern Ireland) 
Organon Pharma (UK) Limited<br />
Tel: +44 (0) 208 159 3medicalinformationuk@organon.com </p>
<p>Denne indlægsseddel blev senest ændret { MM/ÅÅÅÅ } </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.  </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-f2aa2b90d380444519f71c2efd9d6e1e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sycrest Package Leaflet for language en"
Description: "ePI document Bundle for sycrest Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-f2aa2b90d380444519f71c2efd9d6e1e"
* entry[0].resource = composition-en-f2aa2b90d380444519f71c2efd9d6e1e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf2aa2b90d380444519f71c2efd9d6e1e"
* entry[=].resource = mpf2aa2b90d380444519f71c2efd9d6e1e
                            
                    
Instance: bundlepackageleaflet-da-f2aa2b90d380444519f71c2efd9d6e1e
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sycrest Package Leaflet for language da"
Description: "ePI document Bundle for sycrest Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-f2aa2b90d380444519f71c2efd9d6e1e"
* entry[0].resource = composition-da-f2aa2b90d380444519f71c2efd9d6e1e

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf2aa2b90d380444519f71c2efd9d6e1e"
* entry[=].resource = mpf2aa2b90d380444519f71c2efd9d6e1e
                            
                    



Instance: mpf2aa2b90d380444519f71c2efd9d6e1e
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Sycrest 5 mg sublingual tablets"
Description: "Sycrest 5 mg sublingual tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/10/640/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Sycrest 5 mg sublingual tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: f2aa2b90d380444519f71c2efd9d6e1eListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "sycrest"

* status = #current
* mode = #working

* title = "List of all ePIs associated with sycrest"

* subject = Reference(mpf2aa2b90d380444519f71c2efd9d6e1e)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#sycrest "sycrest"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-f2aa2b90d380444519f71c2efd9d6e1e) // sycrest en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-f2aa2b90d380444519f71c2efd9d6e1e) // sycrest da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-f2aa2b90d380444519f71c2efd9d6e1e
InstanceOf: List

* insert f2aa2b90d380444519f71c2efd9d6e1eListRuleset
    